Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4695473 | 0.91 | ALDH1A1 (0.51) | KCNH2TBXA2RKDM4E | |
| SCHEMBL4695917 | 0.90 | NTRK1 (0.47) | ACSS2BRD4PLA2G2ATBXA2R | |
| SCHEMBL4697452 | 0.84 | MTNR1A (0.48) | ACSS2TBXA2R | |
| SCHEMBL4694620 | 0.82 | BRD4 (0.53) | ACSS2BRD4KDM4ETP53MAPT | |
| SCHEMBL4697527 | 0.82 | ALDH1A1 (0.50) | TBXA2R | |
| SCHEMBL4693967 | 0.81 | POLB (0.52) | ACSS2BRD4KDM4EMAPT | |
| SCHEMBL4699300 | 0.79 | MTNR1A (0.47) | ACSS2 | |
| SCHEMBL9122314 | 0.78 | JAK2 (0.54) | ACSS2BRD4KDM4ETP53MAPT | |
| SCHEMBL4696635 | 0.78 | BRD4 (0.53) | ACSS2BRD4PLA2G2ATBXA2RTP53 | |
| SCHEMBL28487262 | 0.77 | L3MBTL1 (0.49) | ACSS2BRD4PLA2G2ATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646614-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2008-09-10 | — | — | EP | claimed |
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | claimed |
| EP-1646614-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2006-04-19 | — | — | EP | claimed |
| WO-2005002520-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2005-01-13 | — | — | WO | claimed |
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNN1 | ACSS2 2658/4885KCNH2 1/4885BRD4 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.